肺癌组织中miRNA-449a的表达及其临床意义

Expression and and its clinical significance of miRNA-449a in lung cancer

目的探讨miRNA-449a在肺癌细胞中的表达及其临床应用价值。方法收集右江民族医学院附属医院2011年1月1日至2013年6月30日收治的58例肺癌患者作为研究对象,采用逆转录荧光定量聚合酶链反应检测miRNA-449a在肺癌组织和癌旁正常组织中的表达量,分析miRNA-449a与临床病理特征的关系,并采用荧光电子显微镜观察miRNA-449a模拟物对体外培养肺癌细胞株95D细胞凋亡的影响。结果鳞癌组和腺癌组miRNA-449a平均表达量均明显低于癌旁正常对照组(t=6.712,P<0.05;t=4.572,P<0.05),其相对表达量与瘤体大小(U=78.412,P=0.012)有关,与患者年龄(U=920.000,P=0.615)、性别(U=800.000,P=0.215)、病理类型(χ2=4.221,P=0.155)和临床分期(U=754.000,P=0.009)无关。与阴性对照组比较,miRNA-449a模拟物可明显促进肺癌细胞的凋亡,且呈剂量依赖性。结论 miRNA-449a在肺癌组织中呈低表达,可诱导肺癌细胞凋亡,发挥抑癌基因的作用,可能成为肺癌早期诊断与治疗的新分子靶标。

Objective To investigate the expression and and its clinical significance of miRNA‐449a in lung cancer. Methods Totally 58 patients with lung cancer were selected as research objects from Affiliated Hospital of Youjiang Medical College for Nationalities on January 1, 2011 to June 30, 2013. The expression of miRNA‐449a in lung cancer tissues and matched normal tissues were detected by real time PCR. And the relationship between clinical pathological features and the level of miRNA‐449a were analysed. Fluorescent electronic microscope was applied to analyze the apoptosis after transfecting mimics of miRNA‐449a into non‐small cell lung cancer. Results The level of miRNA‐449a was significantly lower in squamous carcinoma group and adenocarcinoma group than that of control group（t=6. 712, P〈0. 05 ;t=4. 572, P〈0. 05 ;respectively）. There was correlation between miRNA‐449a and tumor size（U=78. 412, P=0. 012） and no correlation between miRNA‐449a and age（U=920. 000, P=0. 615）, gender（U=800. 000, P=0. 215）, pathological type（χ2 =4. 221, P= 0. 155）and clinic stage（U=754. 000, P= 0. 009）, all P〉0. 05. Compared with negative control group, miRNA‐449a mimics could induce apoptosis of lung cancer cell 95D with dose‐effect dependent. Conclusion miRNA‐449a is lower expression in lung cancer, can induced apoptosis, which maybe play a role as a tumor suppressor gene, and as a new molecular targets of early diagnosis and treatment of lung cancer.